TITLE:
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

CONDITION:
Breast Neoplasms

INTERVENTION:
exemestane (Aromasin)

SUMMARY:

      To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given
      sequentially over 5 years in the adjuvant treatment of postmenopausal women with early
      breast cancer.

      This Pfizer sponsored trial is part of an international collaboration of investigators
      conducting 7 similar yet independent studies in 9 countries. This study is designed to be
      part of the larger TEAM trial where the data from these 7 studies will be combined. A
      pre-specified analysis of the pooled data will be conducted.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 50 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically/cytologically confirmed adenocarcinoma of the breast, followed by
             adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if
             indicated.

          -  Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being
             considered.

        Exclusion Criteria:

          -  Those patients not deemed to have had potentially curative primary surgical treatment
             or one of the following criteria:

          -  Inflammatory breast cancer

          -  Histologically positive supraclavicular nodes

          -  Ulceration/infiltration of local skin metastasis

          -  Neoadjuvant chemotherapy

          -  Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion

          -  ER and PR negative primary tumor or ER/PR unknown status.
      
